Watch More Highlights
Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses phase I/II findings from the MajesTEC-1 trial, which seems to confirm that teclistamab monotherapy induces deep and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Of note for advanced practitioners, this agent is a T-cell–redirecting, bispecific IgG4 antibody that targets both B-cell maturation antigen (BCMA) and CD3 receptors to induce the T-cell–mediated cytotoxicity of BCMA-expressing myeloma cells (Abstract 896).